Trial Search Results

18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. We will assess the uptake of this novel radiopharmaceutical in subjects with breast cancer, lung cancer, glioblastoma multiforme (GBM) and other cancers requiring antiangiogenesis treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanjiv Sam Gambhir

Collaborator: National Cancer Institute (NCI)

Intervention(s):

  • Drug: fludeoxyglucose F 18
  • Drug: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide
  • Diagnostic Test: positron emission tomography
  • Diagnostic Test: computed tomography
  • Diagnostic Test: positron emission tomography
  • Diagnostic Test: computed tomography
  • Other: laboratory biomarker analysis

Phase:

Phase 1/Phase 2

Eligibility


Inclusion Criteria:

   - Provides written informed consent

   - Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and
   neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis
   treatment

   - Able to remain still for duration of each imaging procedure (about one hour)

Exclusion Criteria:

   - Pregnant or nursing

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All